The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models
- 1 January 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 19 (1), 1-14
- https://doi.org/10.1097/00002030-200501030-00001
Abstract
The U.S. Government has pledged to spend $15 billion in Africa and the Caribbean on AIDS. A central focus of this plan is to provide antiretroviral treatment (ART) to millions. Here, we evaluate whether the plan to rollout ART in Africa is likely to generate an epidemic of drug-resistant strains of HIV. We review what has occurred as a result of high usage of ART in developed countries in terms of changes in risky behavior, and the emergence and transmission of drug-resistant HIV. We also review how mathematical models have been used to predict the evolution of drug-resistant HIV epidemics. We then show how models can be used to predict the likely impact of the ART rollout on the evolution of drug-resistant HIV in Africa. At currently planned levels of treatment coverage, we predict that (over the next decade) in Africa: (i) the impact of ART on reducing HIV transmission (and prevalence) is likely to be undetectable (unless accompanied by substantial changes in behavior), (ii) the transmission rate of drug-resistant HIV will be below the WHO surveillance threshold of 5%, and (ii) the majority of cases of drug-resistant HIV that will occur will be due to acquired (and not transmitted) resistance. For the next decade, large-scale surveillance for detecting transmitted resistance in Africa is unnecessary. Instead, we recommend that patients should be closely monitored for acquired resistance, and sentinel surveillance (in a few urban centers) should be used to monitor transmitted resistance.Keywords
This publication has 80 references indexed in Scilit:
- Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in FranceAIDS, 2003
- Limited Transmission of Drug-Resistant HIV Type 1 in 100 Swedish Newly Detected and Drug-Naive Patients Infected with Subtypes A, B, C, D, G, U, and CRF01_AEAIDS Research and Human Retroviruses, 2003
- Drug‐Selected Resistance Mutations and Non‐B Subtypes in Antiretroviral‐Naive Adults with Established Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2003
- Attitudes toward HIV treatments influence unsafe sexual and injection practices among injecting drug usersAIDS, 2003
- Differences in the Frequency of Resistance to Antiretroviral Drug Classes among Human Immunodeficiency Virus Type 1 Clinical IsolatesJournal of Clinical Microbiology, 2003
- No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infectionAIDS, 2003
- Mutations associated with genotypic resistance to antiretroviral therapy in treatment naı̈ve HIV-1 infected patients in GreeceVirus Research, 2002
- Genotypic drug resistance during HIV-1 primary infection in France (1996–1999): frequency and response to treatmentAIDS, 2002
- Increasing incidence of HIV infections among young gay and biseuxal men in VancouverAIDS, 2001
- Drugs, sex and HIV : a mathematical model for New York CityPhilosophical Transactions Of The Royal Society B-Biological Sciences, 1991